Gilead Sciences, Inc.
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Non-GAAP R&D adjustments: $112M in FY2025, down 36.4% from a year earlier.
Latest, FY2025
112
Period ended Dec 31, 2025
Change on a year earlier
-36.4%
176 in FY2024
History
10 years
Since FY2016
Sources
9
Documents cited below
Where the FY2025 figure comes from
“|| Research and development expenses adjustments | 19 | 29 | 112 | 176”
Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Reported in Form 8-K GAAP to Non-GAAP Reconciliation.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Non-GAAP R&D adjustments ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 112 | -36.4% | Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗ |
| FY2024 | Dec 31, 2024 | 176 | -8,900.0% | Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗ |
| FY2023 | Dec 31, 2023 | -2 | -122.2% | Form 8-K (exhibit991earningspressrel.htm, filed 2025-02-11) ↗ |
| FY2022 | Dec 31, 2022 | 9 | -93.4% | Form 8-K (exhibit991earningspressrel.htm, filed 2024-02-06) ↗ |
| FY2021 | Dec 31, 2021 | 137 | -24.7% | Form 8-K (exhibit991earningspressrel.htm, filed 2023-02-02) ↗ |
| FY2020 | Dec 31, 2020 | 182 | -4,650.0% | Form 8-K (exhibit991earningspressrel.htm, filed 2022-02-01) ↗ |
| FY2019 | Dec 31, 2019 | -4 | -100.3% | Form 8-K (exhibit991earningspressrel.htm, filed 2021-02-04) ↗ |
| FY2018 | Dec 31, 2018 | 1,500 | +238.6% | Form 8-K (exhibit991earningspres.htm, filed 2020-02-04) ↗ |
| FY2017 | Dec 31, 2017 | 443 | -67.2% | Form 8-K (exhibit991earningspressrel.htm, filed 2019-02-04) ↗ |
| FY2016 | Dec 31, 2016 | 1,349 | – | Form 8-K (gildq42017exh991.htm, filed 2018-02-06) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Non-GAAP R&D adjustments ($M), annual FY2016–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/ng-adj-rd
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.